| Document Date: 2013-04-02 09:23:57
Open Document File Size: 276,06 KBShare Result on Facebook
City Interstitial Cystitis Lexington / Lexington / / Company Flagship Ventures / Polaris Partners / Flybridge Capital Partners / Third Rock Ventures / TARIS / / Country United States / Canada / / Currency USD / / Event FDA Phase / Funding / / Facility Queens University / Massachusetts Institute of Technology / / IndustryTerm venture capital / pharmaceutical / stage specialty pharmaceutical / / MedicalCondition bladder diseases / overactive bladder / disease / Bladder Disease Bladder diseases / Bladder Pain Syndrome / urinary incontinence / complex bladder diseases / bladder cancer / Interstitial Cystitis / pain syndrome / pain / chronic pelvic pain syndromes / diseases / urinary tract infections / / MusicGroup Ph.D. / / Organization Queens University / Massachusetts Institute of Technology / / Person Michael Cima / Robert Langer Sc / Purnanand Sarma / J. Curtis Nickel / / Position principal investigator / President and CEO / Professor of Urology / / Product lidocaine / LiRIS / LiRIS® / / ProvinceOrState Massachusetts / / URL www.tarisbiomedical.com / /
SocialTag |
TARIS® Announces Dosing of First Patient in Second Phase 2 Clinical Study of LiRIS® in Interstitial Cystitis Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innov